+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Gastroparesis Drugs Market by Drug Class (Anti-Emetic Agents, Botulinum Toxin Injections, Prokinetic Agents), Indication (Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis), Sales Channel - Forecast 2024-2030

  • PDF Icon

    Report

  • 199 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5924669
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gastroparesis Drugs Market size was estimated at USD 4.37 billion in 2023, USD 4.54 billion in 2024, and is expected to grow at a CAGR of 6.61% to reach USD 6.85 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Gastroparesis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Gastroparesis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Gastroparesis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amneal Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., AstraZeneca PLC, Atlantic Healthcare PLC, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Cairn Diagnostics, Evoke Pharma, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Kyowa Kirin International plc, Lupin Limited, Medtronic PLC, Neurogastrx, Inc., Novartis AG, Pfizer, Inc., Processa Pharmaceuticals, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Theravance Biopharma, Vanda Pharmaceuticals Inc., and Viatris Inc.

Market Segmentation & Coverage

This research report categorizes the Gastroparesis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Anti-Emetic Agents
    • Botulinum Toxin Injections
    • Prokinetic Agents
  • Indication
    • Diabetic Gastroparesis
    • Idiopathic Gastroparesis
    • Post-surgical Gastroparesis
  • Sales Channel
    • Offline
      • Hospitals Pharmacies
      • Retail Pharmacies
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Gastroparesis Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Gastroparesis Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Gastroparesis Drugs Market?
  4. What is the market share of the leading vendors in the Gastroparesis Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Gastroparesis Drugs Market?

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Gastroparesis Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in diabetic population across the globe
5.1.1.2. Rising investment in healthcare infrastructure to enhance healthcare accessibility
5.1.2. Restraints
5.1.2.1. High cost of raw materials used in formulation of hyperlipidemia drugs
5.1.3. Opportunities
5.1.3.1. Continuous research & development activities for new drug development
5.1.3.2. Increasing drug approvals by the regulatory authorities worldwide
5.1.4. Challenges
5.1.4.1. Severe side effects associated with the consumption of gastroparesis drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Gastroparesis Drugs Market, by Drug Class
6.1. Introduction
6.2. Anti-Emetic Agents
6.3. Botulinum Toxin Injections
6.4. Prokinetic Agents
7. Gastroparesis Drugs Market, by Indication
7.1. Introduction
7.2. Diabetic Gastroparesis
7.3. Idiopathic Gastroparesis
7.4. Post-surgical Gastroparesis
8. Gastroparesis Drugs Market, by Sales Channel
8.1. Introduction
8.2. Offline
8.3.1. Hospitals Pharmacies
8.3.2. Retail Pharmacies
8.3. Online
9. Americas Gastroparesis Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Gastroparesis Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Gastroparesis Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. AbbVie Inc.
13.1.3. Amneal Pharmaceuticals, Inc.
13.1.4. ANI Pharmaceuticals, Inc.
13.1.5. AstraZeneca PLC
13.1.6. Atlantic Healthcare PLC
13.1.7. Bausch Health Companies Inc.
13.1.8. Bristol-Myers Squibb Company
13.1.9. Cadila Pharmaceuticals Limited
13.1.10. Cairn Diagnostics
13.1.11. Evoke Pharma, Inc.
13.1.12. GlaxoSmithKline PLC
13.1.13. Johnson & Johnson Services, Inc.
13.1.14. Kyowa Kirin International plc
13.1.15. Lupin Limited
13.1.16. Medtronic PLC
13.1.17. Neurogastrx, Inc.
13.1.18. Novartis AG
13.1.19. Pfizer, Inc.
13.1.20. Processa Pharmaceuticals, Inc.
13.1.21. Sanofi S.A.
13.1.22. Takeda Pharmaceutical Company Limited
13.1.23. Theravance Biopharma
13.1.24. Vanda Pharmaceuticals Inc.
13.1.25. Viatris Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GASTROPARESIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GASTROPARESIS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GASTROPARESIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GASTROPARESIS DRUGS MARKET DYNAMICS
FIGURE 7. GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
FIGURE 12. GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. GASTROPARESIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GASTROPARESIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. GASTROPARESIS DRUGS MARKET SIZE, BY ANTI-EMETIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. GASTROPARESIS DRUGS MARKET SIZE, BY BOTULINUM TOXIN INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GASTROPARESIS DRUGS MARKET SIZE, BY PROKINETIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 10. GASTROPARESIS DRUGS MARKET SIZE, BY DIABETIC GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GASTROPARESIS DRUGS MARKET SIZE, BY IDIOPATHIC GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GASTROPARESIS DRUGS MARKET SIZE, BY POST-SURGICAL GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 14. GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 16. GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 32. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 36. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 45. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 54. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 58. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 62. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 66. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 70. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 74. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 78. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 82. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 86. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 90. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 94. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 103. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 107. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 111. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 115. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 119. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 123. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 127. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 131. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 135. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 139. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 143. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 147. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 163. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 167. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 169. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 171. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 175. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 187. GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 188. GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 189. GASTROPARESIS DRUGS MARKET LICENSE & PRICING

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • AbbVie Inc.
  • Amneal Pharmaceuticals, Inc.
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Atlantic Healthcare PLC
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Cairn Diagnostics
  • Evoke Pharma, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin International plc
  • Lupin Limited
  • Medtronic PLC
  • Neurogastrx, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Processa Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma
  • Vanda Pharmaceuticals Inc.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 4.54 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.85 Billion
Compound Annual Growth Rate6.6%
Regions CoveredGlobal

Related Topics

Related Reports

Gastroparesis Drugs Global Market Report 2024 - Product Image

Gastroparesis Drugs Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Gastroparesis Drugs - Global Strategic Business Report - Product Image

Gastroparesis Drugs - Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Diabetic Gastroparesis (DGp) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Diabetic Gastroparesis (DGp) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Global Gastroparesis Drugs Market 2024-2028 - Product Image

Global Gastroparesis Drugs Market 2024-2028

  • Report
  • 166 Pages
  • Global
From
Diabetic Gastroparesis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region - Product Image

Diabetic Gastroparesis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region

  • Report
  • 209 Pages
  • Global

About the Gastroparesis Drug Market

Gastroparesis Drug is a type of drug used to treat gastroparesis, a condition in which the stomach muscles are weakened and unable to properly move food through the digestive system. These drugs are used to reduce symptoms such as nausea, vomiting, bloating, and abdominal pain. Commonly prescribed drugs for gastroparesis include metoclopramide, domperidone, and erythromycin. Other drugs, such as prokinetics, may also be used to help improve gastric emptying. Gastroparesis Drug is a part of the larger Gastrointestinal Drugs market, which includes drugs used to treat a variety of gastrointestinal conditions. These drugs are used to reduce symptoms, improve digestion, and prevent further complications. Commonly prescribed drugs in this market include antacids, proton pump inhibitors, and laxatives. Some companies in the Gastroparesis Drug market include Novartis, GlaxoSmithKline, Pfizer, and Takeda. Other companies, such as Allergan, Merck, and AstraZeneca, also produce drugs for the treatment of gastroparesis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.